Applied DNA Sciences, Inc.(NASDAQ:APDN) (“Applied DNA”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions and nucleic acid-based biotherapeutic development, announced today that its partner, Colorcon, a world leader in the development and supply of film coating systems and excipients, formally launched the On-Dose Authentication capability to provide track and trace functionality for supply chain security. The seamless integration of molecular taggants from Applied DNA Sciences (ADNAS) into an Opadry®fully formulated film coating system significantly reduces the risks associated with counterfeit and falsified medications entering the supply chain.
This first commercial offering is the culmination of extensive collaboration between Colorcon and ADNAS to help pharmaceutical companies enhance patient safety and reduce risk by using intelligent data and analytics gathered from authentication of the dosage form itself. By better understanding the vulnerabilities of a complex global supply chain, drug manufacturers can make informed decisions regarding distribution networks and deploy preventative measures to address counterfeiting and product diversion issues.
Dr. Ali Rajabi-Siahboomi, Vice President/Chief Scientific Officer at Colorcon Inc. says, “With new guidelines from regulators and accessible technology, on-dose solutions provide a more robust and reliable means of identifying and deterring counterfeiting, verifying product authenticity, and ensuring product traceability. Through extensive research and development, Colorcon has created a unique coating system to address this global problem.”
Kelly Boyer, General Manager, Film Coatings at Colorcon Inc. explains, “On-dose authentication technology represents the next generation in pharmaceutical supply-chain security by providing a powerful tool for tracking product from plant to patient. By seamlessly enabling authentication, these digitized coatings confirm the quality and origin of medicines thereby safeguarding both patients and brands.”
Colorcon continues to advance technologies and services to meet industry challenges with innovative solutions. This latest technology yet again demonstrates Colorcon’s leadership in responding to the needs of the pharmaceutical industry, bringing novel solutions that are efficient to deliver with dependable performance.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn . Join our mailing list .
Common stock listed on NASDAQ under the symbol APDN.
About Colorcon
Colorcon is a world leader in the development, supply and technical support of specialty ingredients; formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design, development and manufacture. Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations. Colorcon has 11 manufacturing facilities, 21 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base.
For more information, visit www.colorcon.com .
Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the possibility of a failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, its history of net losses, limited financial resources, limited market acceptance, approval of Applied DNA’s taggant technology by the U.S. Food and Drug Administration or equivalent foreign regulatory agencies as a physical-chemical identifier (PCID) for solid oral dosage forms and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and other reports we file with the SEC, which are available at www.sec.gov . Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
應用DNA科學公司(納斯達克市場代碼:APDN)(納斯達克市場代碼:APDN)是基於聚合酶鏈式反應(Pcr)的dna製造技術的領軍企業,用於產品真實性、可追溯性解決方案和基於核酸的生物治療開發,該公司今天宣佈,其合作伙伴、開發和供應薄膜塗層系統和輔料的世界領先企業Colcocon正式推出了在劑量上進行認證的能力,為供應鏈安全提供跟蹤和跟蹤功能。將應用DNA科學(AdNAS)的分子標記劑無縫集成到Opadry完全配方的薄膜塗層系統中,大大降低了假藥和假藥進入供應鏈的風險。
這第一個商業產品是Colcon和Adnas之間廣泛合作的結果,目的是通過使用從劑型認證收集到的智能數據和分析,幫助製藥公司提高病人的安全性和降低風險。通過更好地瞭解複雜的全球供應鏈的脆弱性,藥品製造商可以就分銷網絡作出知情的決定,並採取預防措施解決假冒和產品轉移問題。
Colcon公司副總裁/首席科學官Ali Rajabi-Siahboomi博士。他説:“有了監管機構的新指導方針和可獲得的技術,在劑量上的解決方案提供了一種更有力和可靠的手段來識別和威懾假冒產品,驗證產品的真實性,並確保產品的可追溯性。通過廣泛的研究和開發,Colocon創造了一個獨特的塗層系統來解決這一全球性問題。“
Kelly Boyer,彩色塗料公司的總經理。解釋:“在劑量認證技術代表了下一代的藥品供應鏈安全,提供了一個強有力的工具跟蹤產品從工廠到病人。通過無縫認證,這些數字化塗層確認了藥品的質量和來源,從而保護了患者和品牌。“
COLOCON繼續推進技術和服務,以創新的解決方案來應對行業的挑戰。這一最新技術再次證明了Colcon在滿足製藥行業需求方面的領導作用,帶來了高效、可靠的解決方案。
關於應用DNA科學
應用dna是一家提供分子技術的供應商,這些技術支持供應鏈安全、防偽和防盜技術、產品基因分型和臨牀前核酸治療藥物候選產品。
應用dna通過提供創新的、基於分子的技術解決方案和服務,幫助保護公司、政府和消費者的產品、品牌、整個供應鏈和知識產權免遭盜竊、偽造、欺詐和轉移,從而使生活變得真實和安全。
欲瞭解更多信息,請訪問adnas.com。在Twitter和LinkedIn上關注我們。加入我們的郵件列表。
在納斯達克上市的普通股代號為APDN。
關於彩色
Colcon公司是開發、供應和技術支持特殊成分的世界領先企業;為製藥工業制定了薄膜塗層系統、改進的釋放技術和功能輔料。我們最好的產品和技術得到我們廣泛的應用數據和增值服務的補充,以支持固體口服劑量設計、開發和製造的各個階段。我們專注於市場問題和技術開發,贏得了Colcon作為首選藥品供應商的國際聲譽。這種聲譽建立在卓越的產品質量、無與倫比的技術支持、廣泛的監管援助和來自多個地點的可靠供應之上。Colcon在全球擁有11個製造設施,21個技術服務實驗室,1200多名員工專門為其客户羣服務。
欲瞭解更多信息,請訪問www.chrocon.com。
前瞻性陳述
應用脱氧核糖核酸在本新聞稿中所作的陳述,可屬1933年“證券法”第27A條、1934年“證券交易法”第21E條及1995年“私人證券訴訟改革法”所指的“前瞻性”性質。前瞻性陳述描述了應用dna的未來計劃、預測、策略和預期,基於假設,涉及許多風險和不確定因素,其中許多風險和不確定性超出了應用dna的控制範圍。實際結果可能與預測的結果大相徑庭,原因是可能無法及時支付其未兑現的可轉換擔保票據,從而導致票據持有人強制執行抵押品補救辦法,其中包括幾乎所有應用dna的資產、淨虧損的歷史、有限的財政資源、有限的市場接受程度、美國食品和藥物管理局或同等的外國監管機構批准應用dna的Taggant技術作為固體口服劑型的物理化學標識符(PCID),以及不時在應用DNA證券交易委員會的報告和文件中詳細説明的各種其他因素,包括我們於12月12日提交的關於表10-K的年度報告,我們向SEC提交的其他報告,見www.sec.gov。除法律另有規定外,應用dna沒有義務公開更新任何前瞻性陳述,以反映本合同日期後的新信息、事件或情況,或反映意外事件的發生。